Fig. 1
From: Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems
ERBB2 gene mutation, amplification, and expression in tumors and cell lines. a ERBB2 mutations were observed in 11 (5 %) out of 220 patients. b Out of 293 GC patients, 38 (13 %) had ERBB2 amplifications, but not deletions. Interestingly, 38 patients did not have MSI-H status. a and b used The Cancer Genome Atlas (TCGA: http://cancergenome.nih.gov/). c Expression of the ERBB2 gene throughout various cancer cell lines. We used the Cancer Cell Line Encyclopedia (CCLE). The X-axis represents origins of the cancer cells, and the numeric followed by the origin indicates the number of cell lines assigned to that origin (www.broadinstitute.org/ccle)